Deep Track Capital, LP
- SEC CIK
- 0001856083
- Latest filing
- Aug 14, 2026
Holdings in Q2 2022
Holdings as of Jun 30, 2022, filed Aug 12, 2022. Long positions only; changes compare share counts with Q1 2022.
- Positions
- 49
- 0 vs. Q1 2022
- Portfolio value
- $1.45B
- −$101.5M (−6.6%) vs. Q1 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| GBTGlobal Blood Therapeutics, Inc. | COM | 3,646,690 | $116.5M | 8.1% | +1,342,007+58.2% | Added | History |
| NVCRNovoCure Ltd | ORD SHS | 1,341,300 | $93.2M | 6.4% | +341,300+34.1% | Added | History |
| TVTXTravere Therapeutics, Inc. | COM | 3,580,700 | $86.8M | 6.0% | +446,197+14.2% | Added | History |
| JAZZJazz Pharmaceuticals plc | SHS USD | 500,000 | $78.0M | 5.4% | −17,051−3.3% | Reduced | History |
| KURAKura Oncology, Inc. | COM | 3,697,969 | $67.8M | 4.7% | +285,969+8.4% | Added | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 905,000 | $64.8M | 4.5% | +119,000+15.1% | Added | History |
| KDNYChinook Therapeutics, Inc. | COM | 3,430,110 | $60.0M | 4.1% | +430,110+14.3% | Added | History |
| BMRNBiomarin Pharmaceutical Inc | COM | 654,365 | $54.2M | 3.7% | +654,365 | New | History |
| FATEFate Therapeutics Inc | COM | 2,018,005 | $50.0M | 3.5% | +18,005+0.9% | Added | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 2,900,000 | $48.7M | 3.4% | +1,044,007+56.3% | Added | History |
| BEAMBeam Therapeutics Inc. | COM | 1,250,000 | $48.4M | 3.3% | +486,250+63.7% | Added | History |
| ISEEIVERIC bio, Inc. | COM | 4,500,000 | $43.3M | 3.0% | 00.0% | Unchanged | History |
| AGENAgenus Inc | COM NEW | 22,241,417 | $43.1M | 3.0% | +8,242,926+58.9% | Added | History |
| ESPREsperion Therapeutics, Inc. | COM | 6,000,000 | $38.2M | 2.6% | 00.0% | Unchanged | History |
| RPTXRepare Therapeutics Inc. | COM | 2,707,662 | $37.9M | 2.6% | +43,645+1.6% | Added | History |
| NUVBNuvation Bio Inc. | COM CL A | 11,471,281 | $37.2M | 2.6% | +10,315,789+892.8% | Added | History |
| IMVTImmunovant, Inc. | COM | 9,455,000 | $36.9M | 2.5% | +2,230,387+30.9% | Added | History |
| NKTXNkarta, Inc. | COM | 2,814,844 | $34.7M | 2.4% | +701,049+33.2% | Added | History |
| NRIXNurix Therapeutics, Inc. | COM | 2,436,164 | $30.9M | 2.1% | +2,436,164 | New | History |
| FMTXForma Therapeutics Holdings, Inc. | SHS | 4,050,000 | $27.9M | 1.9% | +2,390,294+144.0% | Added | History |
| TCDATricida, Inc. | COM | 2,732,117 | $26.4M | 1.8% | +79,424+3.0% | Added | History |
| ACADAcadia Pharmaceuticals Inc | COM | 1,733,130 | $24.4M | 1.7% | +1,733,130 | New | History |
| DYNDyne Therapeutics, Inc. | COM | 3,500,000 | $24.0M | 1.7% | 00.0% | Unchanged | History |
| FDMT4D Molecular Therapeutics, Inc. | COM | 3,140,000 | $21.9M | 1.5% | +691,800+28.3% | Added | History |
| KROSKeros Therapeutics, Inc. | COM | 739,528 | $20.4M | 1.4% | −640,778−46.4% | Reduced | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 1,053,000 | $19.6M | 1.4% | −488,715−31.7% | Reduced | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 1,824,000 | $17.9M | 1.2% | +94,243+5.4% | Added | History |
| DICEDICE Therapeutics, Inc. | COM | 1,042,900 | $16.2M | 1.1% | −207,100−16.6% | Reduced | History |
| INZYInozyme Pharma, Inc. | COM | 3,250,000 | $15.5M | 1.1% | +3,250,000 | New | History |
| SDGRSchrodinger, Inc. | COM | 562,000 | $14.8M | 1.0% | +562,000 | New | History |
| ABOSAcumen Pharmaceuticals, Inc. | COM | 3,100,000 | $14.6M | 1.0% | +500,902+19.3% | Added | History |
| ANABAnaptysbio, Inc | COM | 672,569 | $13.7M | 0.9% | +113,787+20.4% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,170,290 | $13.5M | 0.9% | 00.0% | Unchanged | History |
| ACETAdicet Bio, Inc. | COM | 892,028 | $13.0M | 0.9% | +892,028 | New | History |
| JNCEJounce Therapeutics, Inc. | COM | 4,259,653 | $12.9M | 0.9% | 00.0% | Unchanged | History |
| SLNSilence Therapeutics plc | ADS | 951,580 | $11.3M | 0.8% | 00.0% | Unchanged | History |
| RLMDRelmada Therapeutics, Inc. | COM | 500,000 | $9.49M | 0.7% | +397,883+389.6% | Added | History |
| HOOKHOOKIPA Pharma Inc. | COM | 5,035,998 | $8.21M | 0.6% | 00.0% | Unchanged | History |
| IPSCCentury Therapeutics, Inc. | COM | 924,641 | $7.77M | 0.5% | −1,828−0.2% | Reduced | History |
| DNTHDianthus Therapeutics, Inc. | COM | 5,359,000 | $6.43M | 0.4% | 00.0% | Unchanged | History |
| ASMBAssembly Biosciences, Inc. | COM | 3,000,000 | $6.30M | 0.4% | 00.0% | Unchanged | History |
| SAGESage Therapeutics, Inc. | COM | 171,800 | $5.55M | 0.4% | −503,200−74.5% | Reduced | History |
| PASGPassage BIO, Inc. | COM | 2,320,000 | $5.47M | 0.4% | −1,055,000−31.3% | Reduced | History |
| GHRSGH Research PLC | ORDINARY SHARES | 499,400 | $4.98M | 0.3% | 00.0% | Unchanged | History |
| FULCFulcrum Therapeutics, Inc. | COM | 1,000,000 | $4.90M | 0.3% | +350,000+53.8% | Added | History |
| GRTSGritstone bio, Inc. | COM | 1,720,000 | $4.16M | 0.3% | −1,265,729−42.4% | Reduced | History |
| TNYATenaya Therapeutics, Inc. | COM | 483,836 | $2.72M | 0.2% | −63,087−11.5% | Reduced | History |
| ATYRaTYR PHARMA INC | COM NEW | 290,844 | $823.0K | 0.1% | −737,671−71.7% | Reduced | History |
| VIGLVigil Neuroscience, Inc. | COM | 308,393 | $796.0K | 0.1% | −80,748−20.8% | Reduced | History |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q1 2022 (6)
Positions held at the end of Q1 2022 that are gone from this filing.
| Security | Class | Shares in Q1 2022 | Value in Q1 2022 | % of portfolio in Q1 2022 | History |
|---|---|---|---|---|---|
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 463,663 | $75.7M | 4.9% | History |
| ENTAEnanta Pharmaceuticals Inc | COM | 198,730 | $14.1M | 0.9% | History |
| RXDXPrometheus Biosciences, Inc. | COM | 245,000 | $9.25M | 0.6% | History |
| VERVVerve Therapeutics, Inc. | COM | 102,342 | $2.33M | 0.2% | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 382,559 | $1.59M | 0.1% | History |
| RFLRafael Holdings, Inc. | COM CL B | 104,156 | $261.0K | <0.1% | History |